Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

  • Chronic Lymphocytic Leukemia
Trial Status:

Completed

This trial runs in
Cities
  • Buenos Aires
Trial Identifier:

NCT03059251 ML30187

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

      Hoffmann-La Roche Sponsor
      NCT03059251 , ML30187 Trial Identifier
      Obinutuzumab Treatments
      Chronic Lymphocytic Leukemia Condition
      Official Title

      An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Have received at least one dose of Obinutuzumab as per local label and clinical practice.
      Exclusion Criteria
      • Included in clinical trial

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now